ESC 365 - The effect of CYP2C19 gene polymorphism and clopidogrel dose on clinical outcomes in Asian populations with CAD receiving antiplatelet therapy.

ESC Premium Access

The effect of CYP2C19 gene polymorphism and clopidogrel dose on clinical outcomes in Asian populations with CAD receiving antiplatelet therapy.

Session: Antithrombotic strategies in coronary artery disease

Topic: Thrombosis and coagulation

Speaker: Mr W. Liu (Beijing, CN)

Event: ESC Congress 2017

Congress Presentation

Add to my library

About the speaker

Mr Wei Liu

Beijing Jishuitan Hospital, Beijing (China)

0 follower

9 more presentations in this session

Antithrombotic treatment in patients with stable CAD and AF - 5-year follow-up data from the CLARIFY registry

Speaker: Doctor R. Wakili (Frankfurt, DE)

Application of DAPT score to predict ischaemic and bleeding events in patients who underwent drug-eluting stent implantation: a landmark analysis of large pooled cohort

Speaker: Doctor Y. Yoshikawa (Kyoto, JP)

Growth differentiation factor 15 and bleeding risk with ticagrelor in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54.

Speaker: Doctor M. Bonaca (Aurora, US)

In-hospital switch of P2Y12 drugs in patients presenting with acute coronary syndrome: a meta-analysis of 14 observational and randomized studies including 10961 patients.

Speaker: Doctor M. Bianco (Orbassano, IT)

Optimal long-term antithrombotic treatment of patients with stable coronary artery disease and atrial fibrillation: OLTAT registry

Speaker: Doctor Q. Fischer (Paris, FR)

Access the full session

Antithrombotic strategies in coronary artery disease

Speakers: Mr W. Liu, Doctor R. Wakili, Doctor Y. Yoshikawa, Doctor M. Bonaca, Doctor M. Bianco...

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources